European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1082-1088 , December 2006

Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma

  • B. Kuru

      Affiliations

    • Corresponding Author InformationTel.: +90 532 775 56 68; fax: +90 312 345 49 79.
    • I did not have any financial support, and conflict of interest.

,Accepted 14 June 2006.

References 

  1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer. Cancer. 1989;63:181–187
  2. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival female breast cancer: results of a national survey by the American College Surgeons. Cancer. 1980;45:2917–2924
  3. Vinh-Hung V, Burzykowski T, Cserni G, Voordeckers M, van de Steene J, Storme G. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003;22:697–704
  4. Vinh-Hung V, Verschregen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680–R688
  5. Truong PT, Berthelet E, Lee J, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–2014
  6. Voordeckers V, Vinh-Hung V, van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225–230
  7. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomised clinical trial comparing radical mastectomy and total mastectomy with and without radiation. N Engl J Med. 1985;312:674–681
  8. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-A Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–116
  9. Gemignani ML, Borgen PI. Is there a role for selective axillary dissection in breast cancer?. World J Surg. 2001;25:809–818
  10. van der Wal BCH, Butzelaar RMJH, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and stage II breast cancer. Eur J Surg Oncol. 2002;28:481–489
  11. Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat. 2005;91:11–18
  12. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10:1152–1159
  13. Moorman P, Hamza A, Marks JR, Olson JA. Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative carcinoma. Cancer. 2001;91:2258–2262
  14. Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140–149
  15. Polednak AP. Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg. 2003;237:163–167
  16. McMasters KM. The eternally enigmatic axilla: further controversy about axillary lymph node in breast cancer. Ann Surg Oncol. 2003;10:1128–1130
  17. Vinh-Hung V, Cserni G, Burzykowski T, van de Steene J, Voordeckers M, Storme G. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep. 2003;10:363–368
  18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  19. Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet. 1970;131:79–88
  20. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable model. 3rd ed.. CA: Duxbury Press; 1998;
  21. Hosmer DW, Lemeshow S. Applied survival analysis: regression modelling of time to event data. NY: Wiley-Interscience Publication; 1999;
  22. Gervasoni JE, Taneja C, Chung MA, Cady B. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg. 2000;180:278–283
  23. Jatoi I. Management of the axilla in primary breast cancer. Surg Clin North Am. 1999;79:1061–1073
  24. Dent DM. Axillary lymphadenectomy for breast cancer. Arch Surg. 1996;131:1125–1127
  25. White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg. 1996;183:575–582
  26. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in breast conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of omission and implications for survival. J Am Coll Surg. 1999;188:586–595
  27. Harris J, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat. 1985;5:17–21
  28. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of Institut Curie. Lancet. 1992;339:1245–1248
  29. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol. 1997;66:7–10
  30. Papaioannou AN. Patients with early breast cancer may be harmed from ‘effective’ axillary treatment. Breast Cancer Res Treat. 1985;6:145–147
  31. Camp RL, Rimm EB, Rimm DL. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer. 2000;88:108–113
  32. Weir L, Speers C, D'yachkova , Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20:1793–1799
  33. Germain I, Fortin A, Dagnault A, Vu TT, Larochelle M. The value of the number removed or the ratio of involved nodes as prognostic factor in breast cancer. J Clin Oncol. 2004;22(14S):611;[2004 Asco annual meeting proceedings, July 15 Supplement]; http://meeting.jco.org/cgi/content/abstract/22/14_suppl/611.
  34. Thieleke W, Janni W, Rack B, et al. The number of resected axillary lymph nodes influences the risk for axillary recurrences in node-positive, but not in node-negative patients. [Abstract 396] Eur J Cancer Suppl. 2004;2:171
  35. Hellman S. Stopping metastases at their source. N Engl J Med. 1997;337:996–997
  36. Sigurdson ER. Lymph node dissection: is it diagnostic or therapeutic?. J Clin Oncol. 2003;21:965–967
  37. Fortin A, Larochelle M, Lavardiére J, Lavertu S, Tremblay D. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17:101–109
  38. Grills IS, Kestin LL, Goldstein N, et al. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys. 2003;56:658–670
  39. Costa LSM, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol. 2004;27:304–306
  40. Fisher B, Wolmark N, Bauer N, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152:765–772
  41. International (Ludwig) breast cancer study group . Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet. 1990;335:1565–1568
  42. Yeatman T, Cox CE. The significance of breast cancer lymph node micrometastases. Surg Clin North Am. 1999;8:481–497
  43. Dowlatshahi K, Fan M, Snider HC, Habip FA. Lymph node micrometastases from breast carcinoma. Cancer. 1997;80:1188–1197
  44. Fisher ED, Palekar A, Rockette H, Redmond C, Fisher B. Pathologic findings from the national surgical adjuvant breast project (protocol no. 4) V. Significance of axillary nodal micro- and macrometastasis. Cancer. 1978;42:2032–2038
  45. Weaver DL, Krag DN, Ashigaka T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma. Cancer. 2000;88:1099–1107
  46. Colleoni M, Rotsmensz N, Peruzzotti G, et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005;23:1379–1389
  47. Morrow M. Is axillary dissection necessary after positive sentinel node biopsy? Yes!. Ann Surg Oncol. 2001;8(9 Suppl.):74S–76S
  48. Morrow M. A survival benefit from axillary dissection: was Halsted correct?. Ann Surg Oncol. 1999;6:17–18
  49. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast. 2006;15:3–8

☆ This study was performed at Ankara Oncology Education and Research Hospital, Ankara, Turkey.

PII: S0748-7983(06)00240-X

doi: 10.1016/j.ejso.2006.06.005

European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1082-1088 , December 2006

Article Tools

* Image Usage & Resolution